Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Deferred Tax: 2014-2019

Historic Long-Term Deferred Tax for Zevra Therapeutics (ZVRA) over the last 4 years, with Dec 2019 value amounting to $67.7 million.

  • Zevra Therapeutics' Long-Term Deferred Tax rose 12.20% to $67.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $67.7 million, marking a year-over-year increase of 12.20%. This contributed to the annual value of $67.7 million for FY2019, which is 12.20% up from last year.
  • As of FY2019, Zevra Therapeutics' Long-Term Deferred Tax stood at $67.7 million, which was up 12.20% from $60.4 million recorded in FY2018.
  • In the past 5 years, Zevra Therapeutics' Long-Term Deferred Tax registered a high of $67.7 million during FY2019, and its lowest value of $29.1 million during FY2015.
  • Its 2-year average for Long-Term Deferred Tax is $64.0 million, with a median of $64.0 million in 2018.
  • Data for Zevra Therapeutics' Long-Term Deferred Tax shows a peak YoY soared of 59.33% (in 2015) over the last 5 years.
  • Yearly analysis of 3 years shows Zevra Therapeutics' Long-Term Deferred Tax stood at $29.1 million in 2015, then reached $60.4 million in 2018, then grew by 12.20% to $67.7 million in 2019.